[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

LT3157534T - Acetilcholinesterazės inhibitoriai, skirti dermatologinių būklių gydymui - Google Patents

Acetilcholinesterazės inhibitoriai, skirti dermatologinių būklių gydymui

Info

Publication number
LT3157534T
LT3157534T LTEPPCT/US2015/036448T LT15036448T LT3157534T LT 3157534 T LT3157534 T LT 3157534T LT 15036448 T LT15036448 T LT 15036448T LT 3157534 T LT3157534 T LT 3157534T
Authority
LT
Lithuania
Prior art keywords
treatment
acetylcholinesterase inhibitors
dermatological conditions
dermatological
conditions
Prior art date
Application number
LTEPPCT/US2015/036448T
Other languages
English (en)
Inventor
Frank Anthony SPALLITTA
Original Assignee
Attillaps Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attillaps Holdings filed Critical Attillaps Holdings
Publication of LT3157534T publication Critical patent/LT3157534T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2015/036448T 2014-06-19 2015-06-18 Acetilcholinesterazės inhibitoriai, skirti dermatologinių būklių gydymui LT3157534T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462014520P 2014-06-19 2014-06-19
PCT/US2015/036448 WO2015195928A1 (en) 2014-06-19 2015-06-18 Acetylcholinesterase inhibitors for treatment of dermatological conditions

Publications (1)

Publication Number Publication Date
LT3157534T true LT3157534T (lt) 2022-09-12

Family

ID=54936099

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2015/036448T LT3157534T (lt) 2014-06-19 2015-06-18 Acetilcholinesterazės inhibitoriai, skirti dermatologinių būklių gydymui

Country Status (16)

Country Link
US (3) US10500183B2 (lt)
EP (2) EP4088724B1 (lt)
AU (1) AU2015277038B2 (lt)
CA (1) CA2952838C (lt)
CY (1) CY1126038T1 (lt)
DK (1) DK3157534T3 (lt)
ES (1) ES2925021T3 (lt)
HR (1) HRP20220854T1 (lt)
HU (1) HUE059303T2 (lt)
LT (1) LT3157534T (lt)
PL (1) PL3157534T3 (lt)
PT (1) PT3157534T (lt)
RS (1) RS63433B1 (lt)
SI (1) SI3157534T1 (lt)
WO (1) WO2015195928A1 (lt)
ZA (1) ZA201700183B (lt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3030084A4 (en) * 2013-07-29 2016-07-27 Attillaps Holdings Organophosphates for the treatment of skin disorders
US11446241B2 (en) * 2013-07-29 2022-09-20 Attillaps Holdings Inc. Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
WO2019126541A1 (en) * 2017-12-20 2019-06-27 Attillaps Holdings Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
LT3157534T (lt) 2014-06-19 2022-09-12 Attillaps Holdings Acetilcholinesterazės inhibitoriai, skirti dermatologinių būklių gydymui
CN109414434A (zh) * 2016-05-13 2019-03-01 德尔诺瓦股份有限公司 化学去神经化所致的副作用的治疗
CN109200051A (zh) * 2017-07-03 2019-01-15 南京和博生物医药有限公司 石杉碱甲及其类似物作为治疗炎症性疾病药物的用途
BE1025705B1 (fr) 2017-09-12 2019-06-18 Cosucra Groupe Warcoing Sa Amélioration de la maladie et des conditions générales de la volaille et du bétail à l'aide d'une racine chicorée séchée
US10835517B2 (en) 2017-12-15 2020-11-17 Tarsus Pharmaceuticals, Inc. Methods for treating ocular demodex using isoxazoline parasiticide formulations
WO2019136225A1 (en) * 2018-01-05 2019-07-11 Attillaps Holdings Treating dermatological conditions with chloroquine and/or hydroxychloroquine
US20210077559A1 (en) * 2018-01-05 2021-03-18 Attillaps Holdings Treating Autoimmune Disorders with Acetylcholinesterase Inhibitors
WO2021102072A1 (en) * 2019-11-19 2021-05-27 Rythera Therapeutics, Inc. Composition and method for skin treatment
WO2021189077A1 (en) * 2020-03-18 2021-09-23 Chemistryrx Methods for treating acne
CN114099490A (zh) * 2021-12-30 2022-03-01 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 卡巴拉汀在制备促进缺血超长随意皮瓣存活的药物的作用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
DE4217396A1 (de) 1992-05-26 1993-12-02 Bayer Ag Metrifonat enthaltendes Arzneimittel
DE69925461T2 (de) 1998-02-09 2006-04-27 Bracco International B.V. Zielgerichtete abgabe von biologische-aktive medien
US5952372A (en) 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6133310A (en) 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US20030040504A1 (en) 2001-05-09 2003-02-27 Gans Eugene H. Ectoparasiticidal compositions and methods of their use
EP1476121A4 (en) * 2002-02-08 2010-10-27 Merck Sharp & Dohme TOPICAL IVERMECTIN COMPOSITION
MXPA04013003A (es) 2002-06-19 2005-09-12 Fideline Composiciones de alomonas repelentes y kairomonas atractivas, para controlar aracnidos.
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US7899527B2 (en) * 2004-05-13 2011-03-01 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase
WO2006017263A1 (en) * 2004-07-12 2006-02-16 Taro Pharmaceutical Industries Ltd. Topical gel formulation comprising organophosphate insecticide and its preparation thereof
GB2419093A (en) 2004-10-12 2006-04-19 Ernir Snorrason Acetylcholinesterase inhibitors for the treatment of skin
US9186345B2 (en) * 2004-10-12 2015-11-17 Hakon Hakonarson Method of treating skin diseases
US20090214676A1 (en) 2005-04-30 2009-08-27 Tissuetech, Inc. Method for treating ocular demodex
FR2886851B1 (fr) 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
ZA200901429B (en) 2006-09-01 2010-06-30 Du Pont Local topical administration formulations containing indoxacarb
US20080292560A1 (en) 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
MX2009007637A (es) 2007-01-16 2009-09-28 Tyratech Inc Composiciones y metodos para control de pestes.
US20130052271A1 (en) * 2011-08-29 2013-02-28 Richard S. Sternasty Compositions and Methods for Treating Pain
FR2915489B1 (fr) * 2007-04-27 2009-07-31 Univ Henri Poincare Nancy I Et Phosphotriesterases hyperthermophiles mutees et leurs utilisations
WO2008134712A2 (en) 2007-04-30 2008-11-06 Living Proof, Inc. Use of matrix metalloproteinase inhibitors in skin care
US7919522B2 (en) 2007-05-03 2011-04-05 Merial Limited Compositions comprising C-13 alkoxyether macrolide compounds and phenylpyrazole compounds
AU2008254424B2 (en) 2007-05-18 2012-12-20 Vivus, Inc. Novel combinations comprising a phosphodiesterase-5 inhibitor and their use
GB0713790D0 (en) 2007-07-16 2007-08-22 Nettforsk As Method
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
US8128968B2 (en) * 2007-08-29 2012-03-06 Tissuetech, Inc. Compositions and methods for treating Demodex infestations
TW200924647A (en) 2007-08-30 2009-06-16 Schering Plough Ltd Local topical administration formulations containing fipronil
DE102007043006B4 (de) 2007-09-06 2010-04-08 Freie Universität Berlin Vorrichtung und Verfahren zur Exponierung eines Insekts mit einem Wirkstoff sowie Verfahren zur Bestimmung der Wirkung eines Wirkstoffs auf ein Insekt
EP2072501A1 (en) 2007-12-21 2009-06-24 Bayer CropScience AG Aminobenzamide derivatives as useful agents for controlling animal parasites
ES2700986T3 (es) 2008-04-15 2019-02-20 Lucas Meyer Cosmetics Canada Inc Composiciones cosméticas que comprenden exopolisacáridos derivados de tapices microbianos, y uso de las mismas
US8247405B2 (en) 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
JPWO2012011591A1 (ja) * 2010-07-23 2013-09-09 武田薬品工業株式会社 縮合複素環化合物およびその用途
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
JP2014028758A (ja) 2010-11-19 2014-02-13 Nissan Chem Ind Ltd 寄生虫及び衛生害虫防除剤
MX2013011375A (es) 2011-03-31 2013-12-09 Bayer Cropscience Lp Mezclas de plagicidas.
FR2975004B1 (fr) * 2011-05-13 2013-06-28 Expanscience Lab Nouvel actif anti-rougeurs et compositions cosmetiques le comprenant
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
AR088668A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
JO3626B1 (ar) 2012-02-23 2020-08-27 Merial Inc تركيبات موضعية تحتوي على فيبرونيل و بيرميثرين و طرق استخدامها
WO2014160423A1 (en) * 2013-03-13 2014-10-02 Genetic Disease Investigators, LLC Methods and compositions for correction of organ dysfunction
EP3030084A4 (en) 2013-07-29 2016-07-27 Attillaps Holdings Organophosphates for the treatment of skin disorders
US11446241B2 (en) * 2013-07-29 2022-09-20 Attillaps Holdings Inc. Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
LT3157534T (lt) * 2014-06-19 2022-09-12 Attillaps Holdings Acetilcholinesterazės inhibitoriai, skirti dermatologinių būklių gydymui

Also Published As

Publication number Publication date
CA2952838C (en) 2023-09-05
US20220096420A1 (en) 2022-03-31
US20170135978A1 (en) 2017-05-18
AU2015277038B2 (en) 2020-09-17
CA2952838A1 (en) 2015-12-23
EP3157534A1 (en) 2017-04-26
HUE059303T2 (hu) 2022-11-28
US10500183B2 (en) 2019-12-10
EP3157534A4 (en) 2018-03-14
EP4088724A1 (en) 2022-11-16
HRP20220854T1 (hr) 2022-10-14
RS63433B1 (sr) 2022-08-31
EP3157534B1 (en) 2022-07-06
WO2015195928A1 (en) 2015-12-23
DK3157534T3 (da) 2022-08-22
ES2925021T3 (es) 2022-10-13
PL3157534T3 (pl) 2022-09-12
ZA201700183B (en) 2020-05-27
US11045442B2 (en) 2021-06-29
CY1126038T1 (el) 2023-11-15
US20200281885A1 (en) 2020-09-10
PT3157534T (pt) 2022-08-04
SI3157534T1 (sl) 2022-08-31
EP4088724B1 (en) 2024-10-23
AU2015277038A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
IL251584B (en) Dihydropyrrolopyridines ror–gamma inhibitors
IL253945A0 (en) kdm1a inhibitors to treat the disease
IL246902A0 (en) Dihydropyrrolopyridine ror–gamma inhibitors
ZA201700183B (en) Acetylcholinesterase inhibitors for treatment of dermatological conditions
GB201701673D0 (en) Methods of well treatment
IL285077A (en) Compounds for the treatment of cancer
SG11201607130RA (en) Combination method for treatment of cancer
GB201410116D0 (en) Method of treatment
PL3164394T3 (pl) Inhibitory GLS1 do leczenia chorób
IL253028B (en) treatment method
GB201416832D0 (en) Methods of treatment
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201421982D0 (en) Method of treatment
GB201421980D0 (en) Method of treatment
GB201415331D0 (en) Method of treatment
GB201414780D0 (en) Method Of Treatment
GB201421812D0 (en) New therapeutic uses of enzyme inhibitors
GB201410529D0 (en) New therapeutic uses of enzyme inhibitors